The effectiveness of Topamax and Depakine in treating epileptic patients

Outcomes of sustained-release formulation of valproate and topiramate monotherapy in patients with epilepsy: a multi-centre, cohort study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-12002147

Enrollment

Unknown

Registered

2012-05-02

Start date

2000-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Interventions

SRVPA:SRVPA

TPM:TPM

Eligibility

Sex/Gender

All

Age

2 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with a definite diagnosis of epilepsy, treated with SRVPA or topiramate as monotherapy, between 2 to 75 years old, were enrolled in this study.

Exclusion criteria

Exclusion criteria: The exclusion criteria included the following: epileptic syndromes; only acute symptomatic or non-epileptic seizures; a history of psychiatric or mood disorders; clinically significant laboratory abnormalities, including abnormal liver function, abnormal haematological system function, abnormal kidney function, abnormal endocrine system function, or heart disease; and clinician or the patient feeling that the treatment was contraindicated.

Design outcomes

Primary

Measure	Time frame
Retention rate;Time to first seizur;	—

Secondary

Measure	Time frame
Time to 12-month remission;Time to 24-month remission;	—

Countries

China

Contacts

Public ContactWang, Xuefeng

The first affiliated hospital of Chongqing Medical University

kudosai@163.com+86 023 89012878

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026